2015;(9):CD004069
4.1 Signals of adverse events We observed that metabolic and nutritional adverse reactions were more frequently reported by females (Table 1), which has previously been interpreted as a greater inclination for females to report AEs to FAERS ( Exenatide (n = 10,450), dulaglutide (n = 4,847), liraglutide (n = 2,860), semaglutide (n = 2,905), and tirzepatide (n = 1,089) had the greatest number of reported AEs, and the highest number of AEs reported on the effects of appetite, as reflected in our analyses of the HLT stratum (Supplementary Table S2)
Nonetheless, our observed association between thyroid hormone over-replacement and new-onset AF/Aflutter aligns with a nested casecontrol study of 183,360 patients: compared to low levothyroxine exposure, high and medium exposure was associated with 29% (95% CI 1.231.35) and 8% (95% CI 1.041.11) increased odds of AF, respectively [36]
It can reduce appetite, making it easier to eat less and lose weight